Company intelligence / Profile preview
Zalgen Labs
Frederick, Maryland, United Stateszalgen.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Zalgen Labs develops and supplies recombinant viral antigens, monoclonal antibodies, and immunodiagnostic kits (e.g., for Lassa fever, Ebola, SARS‑CoV‑2) and is advancing a structure-guided, preclinical bivalent vaccine program targeting Lassa virus and Ebola virus in collaboration with academic and global health partners.[2][3][4][5]
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineProteinRecombinant proteinMonoclonal antibodyDiagnostic kitDevice
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Coalition for Epidemic Preparedness Innovations (CEPI)[2][4]VHFC (Viral Hemorrhagic Fever Consortium) partners, including Tulane University[2]NIH/NIAID (funding and collaborative vaccine development support)[2]
Beyond the preview
Go deeper on Zalgen Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zalgen Labs.